Drug Profile
Research programme: Alzheimer's disease vaccine - ID Pharma/Eisai
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator DNAVEC Corporation; Eisai Co Ltd
- Developer Eisai Co Ltd; ID Pharma
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Japan (Transmucosal)
- 13 Apr 2006 Preclinical trials in Alzheimer's disease in Japan (unspecified route)